RS56485B1 - 6-okso-1,6-dihidro-piridazin derivat za upotrebu u tretmanu hepatocelularnog karcinoma (hcc) - Google Patents

6-okso-1,6-dihidro-piridazin derivat za upotrebu u tretmanu hepatocelularnog karcinoma (hcc)

Info

Publication number
RS56485B1
RS56485B1 RS20171129A RSP20171129A RS56485B1 RS 56485 B1 RS56485 B1 RS 56485B1 RS 20171129 A RS20171129 A RS 20171129A RS P20171129 A RSP20171129 A RS P20171129A RS 56485 B1 RS56485 B1 RS 56485B1
Authority
RS
Serbia
Prior art keywords
oxo
dihydro
benzyl
ylmethoxy
pyrimidin
Prior art date
Application number
RS20171129A
Other languages
English (en)
Serbian (sr)
Inventor
Manja Friese-Hamim
Friedhelm Bladt
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of RS56485B1 publication Critical patent/RS56485B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20171129A 2012-11-02 2013-10-04 6-okso-1,6-dihidro-piridazin derivat za upotrebu u tretmanu hepatocelularnog karcinoma (hcc) RS56485B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12007494 2012-11-02
EP13776720.8A EP2914264B1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
PCT/EP2013/002998 WO2014067610A1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)

Publications (1)

Publication Number Publication Date
RS56485B1 true RS56485B1 (sr) 2018-01-31

Family

ID=47143496

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20171129A RS56485B1 (sr) 2012-11-02 2013-10-04 6-okso-1,6-dihidro-piridazin derivat za upotrebu u tretmanu hepatocelularnog karcinoma (hcc)

Country Status (26)

Country Link
US (1) US20150283137A1 (cg-RX-API-DMAC10.html)
EP (1) EP2914264B1 (cg-RX-API-DMAC10.html)
JP (1) JP6255028B2 (cg-RX-API-DMAC10.html)
KR (1) KR102131588B1 (cg-RX-API-DMAC10.html)
CN (1) CN104768553A (cg-RX-API-DMAC10.html)
AR (1) AR093318A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013339823B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015008279A2 (cg-RX-API-DMAC10.html)
CA (1) CA2890273C (cg-RX-API-DMAC10.html)
DK (1) DK2914264T3 (cg-RX-API-DMAC10.html)
ES (1) ES2646913T3 (cg-RX-API-DMAC10.html)
HK (1) HK1211869A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20171295T1 (cg-RX-API-DMAC10.html)
HU (1) HUE035483T2 (cg-RX-API-DMAC10.html)
IL (1) IL238536B (cg-RX-API-DMAC10.html)
LT (1) LT2914264T (cg-RX-API-DMAC10.html)
MX (1) MX354518B (cg-RX-API-DMAC10.html)
NO (1) NO2914264T3 (cg-RX-API-DMAC10.html)
PL (1) PL2914264T3 (cg-RX-API-DMAC10.html)
PT (1) PT2914264T (cg-RX-API-DMAC10.html)
RS (1) RS56485B1 (cg-RX-API-DMAC10.html)
RU (1) RU2650679C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201503214YA (cg-RX-API-DMAC10.html)
SI (1) SI2914264T1 (cg-RX-API-DMAC10.html)
WO (1) WO2014067610A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201503924B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016002932B1 (pt) 2013-08-14 2021-02-23 Yugenkaisha Japan Tsusyo sistema de cultivo hidropônico
HRP20231548T1 (hr) * 2019-07-10 2024-03-15 Merck Patent Gmbh Farmaceutski pripravak
EP4045009A4 (en) 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
CA2949515C (en) * 2009-01-08 2018-10-23 Axel Becker Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
CN104768553A (zh) 2015-07-08
MX2015005265A (es) 2015-07-17
MX354518B (es) 2018-03-08
RU2015120692A (ru) 2016-12-27
JP2015536957A (ja) 2015-12-24
CA2890273A1 (en) 2014-05-08
ZA201503924B (en) 2020-11-25
DK2914264T3 (en) 2017-09-11
SG11201503214YA (en) 2015-05-28
EP2914264B1 (en) 2017-08-09
IL238536A0 (en) 2015-06-30
HK1211869A1 (en) 2016-06-03
EP2914264A1 (en) 2015-09-09
BR112015008279A2 (pt) 2017-07-04
KR20150079942A (ko) 2015-07-08
SI2914264T1 (sl) 2017-12-29
PL2914264T3 (pl) 2017-12-29
AR093318A1 (es) 2015-05-27
HRP20171295T1 (hr) 2017-10-20
ES2646913T3 (es) 2017-12-18
RU2650679C2 (ru) 2018-04-17
KR102131588B1 (ko) 2020-07-08
LT2914264T (lt) 2017-11-10
NO2914264T3 (cg-RX-API-DMAC10.html) 2018-01-06
IL238536B (en) 2019-01-31
AU2013339823A1 (en) 2015-06-18
US20150283137A1 (en) 2015-10-08
WO2014067610A1 (en) 2014-05-08
AU2013339823B2 (en) 2018-01-04
HUE035483T2 (hu) 2018-05-02
CA2890273C (en) 2021-10-26
PT2914264T (pt) 2017-11-14
JP6255028B2 (ja) 2017-12-27

Similar Documents

Publication Publication Date Title
AU2013234767B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
AU2015360006B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
EP2914264B1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
US20190388423A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor
AU2013329865B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor
TW201609102A (zh) 具有抗癌活性之6-側氧基-1,6-二氫嗒衍生物與吉非替尼(gefitinib)之組合
TW201609103A (zh) 用於治療腎細胞惡性腫瘤(rcc)之6-側氧基-1,6-二氫嗒衍生物